Novel Anticancer Drug Protocols

  • John K. Buolamwini
  • Alex A. Adjei

Part of the Methods in Molecular Medicine book series (MIMM, volume 85)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. John K. Buolamwini, Haregewein Assefa
      Pages 3-28
  3. Kinase Inhibitor Discovery Protocols

    1. Front Matter
      Pages 29-29
    2. Judith S. Sebolt-Leopold, Keri Van Becelaere, Kenneth Hook, Roman Herrera
      Pages 31-38
    3. Adrian M. Senderowicz, Tyler Lahusen
      Pages 39-48
  4. Angiogenesis and Metastasis Protocols

    1. Front Matter
      Pages 57-57
    2. Ronald S. Go, Whyte G. Owen
      Pages 59-64
    3. Gregory I. Frost, Per Borgström
      Pages 65-78
    4. Martin Sattler, Elizabeth Quackenbush, Ravi Salgia
      Pages 87-105
    5. Jianing Zhang, Michiko N. Fukuda
      Pages 117-121
    6. Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan, Amy Ostendorf, Stephen D. Gillies, Paul M. Sondel
      Pages 123-131
  5. Immunohistochemical Assays in the Clinical Setting

    1. Front Matter
      Pages 133-133
    2. Shazli N. Malik, Roble G. Bedolla, Manuel Hidalgo, Michael G. Brattain, Jeffrey I. Kreisberg
      Pages 135-140
  6. Protein Chaperoning/Degradation Protocols

    1. Front Matter
      Pages 147-147
    2. Wynne Aherne, Alison Maloney, Chris Prodromou, Martin G. Rowlands, Anthea Hardcastle, Katherine Boxall et al.
      Pages 149-161

About this book

Introduction

With many potential molecular targets of anticancer agents already identified and many more yet to be discovered, the great challenges are now to successfully validate them, to devise relevant assays, and to translate the results into effective medicines for cancer patients. In Novel Anticancer Drug Protocols, expert basic researchers and clinicians from both industry and academia not only survey the whole arena of novel antitumor drug targets, but also present a wide-ranging selection of the key techniques currently being applied throughout anticancer drug discovery and development. Described in step-by-step detail to ensure successful results, these methods are employed in experiments involving such central topics as immunotherapy, angiogenesis, cancer metastasis, the cell cycle, signal transduction inhibitors, apoptosis, antibodies, antisense molecules, microarray gene expression analysis, flow cytometry, and PET imaging for cancer target validation. There are also proven methods for the preclinical identification of drug targets and for target validation during the clinical trials of novel agents. Each method provides background information, easy-to-follow instructions, notes on avoiding pitfalls, and alternative procedures.
Eminently practical and user-friendly, Novel Anticancer Drug Protocols offers all researchers involved in cancer drug development a blend of the critical preclinical and clinical assays needed for the target validation and discovery of novel agents today.

Editors and affiliations

  • John K. Buolamwini
    • 1
  • Alex A. Adjei
    • 2
  1. 1.University of Tennessee Health Science CenterMemphis
  2. 2.Mayo Clinic and FoundationRochester

Bibliographic information

  • DOI https://doi.org/10.1385/1592593801
  • Copyright Information Humana Press 2003
  • Publisher Name Humana Press
  • eBook Packages Springer Protocols
  • Print ISBN 978-0-89603-963-6
  • Online ISBN 978-1-59259-380-4
  • Series Print ISSN 1543-1894
  • Series Online ISSN 1940-6037
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma